Artemis SCID — autosomal recessive severe combined immunodeficiency caused by biallelic loss-of-function mutations in the DCLRE1C gene encoding the Artemis protein (also designated DNA cross-link repair 1C protein, Artemis nuclease, SNM1C), a 5'-to-3' exonuclease and endonuclease that functions as an indispensable cofactor for DNA-PKcs (DNA-dependent protein kinase catalytic subunit) in the resolution of DNA hairpin intermediates formed during V(D)J recombination and in the repair of DNA double-strand breaks generated by ionizing radiation, radiomimetic drugs, and endogenous replication stress — renders T-cell and B-cell progenitors unable to complete V(D)J recombination of T-cell receptor (TCR) and immunoglobulin (Ig) genes because the DNA hairpin structures formed at coding-end junctions during RAG1/RAG2-mediated cleavage cannot be opened and resolved without functional Artemis nuclease activity, producing a T-B-NK+ immunophenotype in which T cells and B cells are absent (as in RAG1/RAG2 SCID) but NK cells develop normally (since NK-cell differentiation does not require lymphocyte-specific V(D)J recombination), and additionally conferring a critical clinical characteristic that fundamentally distinguishes Artemis SCID from all other SCID forms: radiosensitivity — the consequence of impaired DNA double-strand break repair in all somatic cells, not only lymphocyte progenitors, meaning that Artemis-deficient patients cannot adequately repair the DNA damage caused by ionizing radiation, radiomimetic alkylating agents (busulfan, cyclophosphamide at conventional myeloablative doses), and topoisomerase II inhibitors, with the clinical implication that standard myeloablative HSCT conditioning regimens used in other SCID forms cause excessive and life-threatening toxicity in Artemis SCID patients — hepatic veno-occlusive disease, severe mucositis, excessive pulmonary toxicity, and treatment-related mortality rates significantly higher than in non-radiosensitive SCID — making reduced-intensity conditioning (RIC) the preferred approach for Artemis SCID HSCT, using lower doses of busulfan, avoiding full-dose cyclophosphamide, using alemtuzumab or fludarabine-based serotherapy, and accepting higher rates of mixed chimerism as the price of reduced conditioning toxicity; additionally notable for significantly elevated prevalence in Navajo Nation and Apache populations of the American Southwest, where a founder mutation in DCLRE1C (specifically a deletion encompassing exons 1–3) has been identified in a large proportion of affected individuals — Navajo SCID or Apache SCID referring to this founder-effect presentation in a population with an estimated SCID prevalence of 1 in 2,000 live births (compared to approximately 1 in 50,000–100,000 in the general population), creating a population-specific public health context for TREC newborn screening programs in states with significant Indigenous populations and for HSCT programs with Navajo/Apache patient catchment areas; presenting with the T-B-NK+ SCID clinical picture: absent T cells and B cells from birth, profound lymphopenia (absolute lymphocyte count often below 500/μL), recurrent life-threatening infections from the first months of life — Pneumocystis jirovecii pneumonia, severe viral infections, invasive fungal disease, disseminated BCG disease — requiring urgent protective isolation and HSCT; treated with HSCT (curative) using reduced-intensity conditioning protocols; emerging gene therapy approaches under active investigation.
Artemis SCID technology platforms — whether serving newborn screening programs processing TREC-low results with the T-B-NK+ immunophenotype pattern characteristic of V(D)J recombination defects, genetic testing services performing DCLRE1C sequencing including founder mutation analysis for Navajo/Apache patients, pediatric immunology centers coordinating pre-HSCT radiosensitivity documentation that is critical for conditioning protocol selection, HSCT programs implementing reduced-intensity conditioning protocols specifically calibrated to the Artemis DNA repair defect, infection prophylaxis coordination platforms managing TMP-SMX, antifungal, CMV, and IVIG supplementation without gaps during immune-deficient intervals, post-transplant monitoring platforms tracking T-cell and B-cell reconstitution from zero-lymphocyte baseline with careful attention to the mixed chimerism patterns that are more common after RIC in Artemis SCID than after myeloablative conditioning in other SCID forms, opportunistic infection prophylaxis platforms providing enhanced surveillance for CMV and fungal infections in the post-RIC immune-deficient interval, growth and developmental assessment scheduling platforms, live vaccine contraindication alert systems, and population-specific screening programs for Navajo/Apache communities managing cascade newborn screening and family testing — must maintain the availability and performance that urgent TREC-low alert workflows, radiosensitivity documentation, reduced-intensity conditioning monitoring, and Navajo/Apache-specific population screening impose. This guide explains why Artemis SCID tech platforms require specialized monitoring, what to monitor, and how to build a monitoring strategy calibrated to the radiosensitivity complexity and population-specific dimensions of Artemis SCID management.
Why Artemis SCID Tech Platforms Require Specialized Monitoring Attention
Artemis SCID is clinically urgent and immunologically straightforward in its TREC-low presentation and T-B-NK+ immunophenotype, but carries platform requirements that extend beyond standard SCID monitoring through the radiosensitivity documentation imperative, the reduced-intensity conditioning protocol management complexity, the Navajo/Apache population health dimension, and the mixed chimerism monitoring requirements that characterize post-RIC Artemis SCID HSCT outcomes.
Radiosensitivity documentation platforms record the critical HSCT conditioning determinant. The most consequential piece of clinical information for an Artemis SCID patient is the radiosensitivity designation — documenting that this patient's DNA repair defect precludes standard myeloablative conditioning and mandates reduced-intensity conditioning protocol selection. Radiosensitivity documentation must be captured in the HSCT planning record before conditioning protocol selection and must transfer correctly between newborn nursery, pediatric immunology, HSCT, and referring hospital records. A radiosensitivity documentation platform failure that allows a conditioning protocol planning process to proceed without flagging the Artemis SCID radiosensitivity designation is a patient safety risk that could result in application of standard busulfan/cyclophosphamide myeloablative conditioning to a patient whose DNA repair defect precludes it, with treatment-related mortality as a potential consequence. Monitor radiosensitivity documentation systems with immediate alerting.
Reduced-intensity conditioning monitoring platforms require specialized pharmacokinetic integration. RIC protocols for Artemis SCID use lower busulfan cumulative doses (targeted by area-under-curve pharmacokinetics monitoring), fludarabine-based lymphodepletion, and serotherapy (alemtuzumab or anti-thymocyte globulin) to achieve sufficient myelosuppression for donor engraftment without the DNA damage burden of full myeloablative conditioning. Busulfan pharmacokinetics monitoring requires plasma concentration measurement after the first busulfan dose with real-time dose adjustment before subsequent doses — a time-sensitive workflow that must complete within hours to allow dose modification before the next scheduled administration. Conditioning protocol monitoring platforms supporting this workflow must be available without interruption during the conditioning admission. Monitor during conditioning treatment periods with immediate alerting.
Navajo/Apache population screening programs require culturally adapted platform workflows. The elevated Artemis SCID prevalence in Navajo Nation and Apache communities (driven by DCLRE1C founder mutations) means that TREC newborn screening programs in affected states (Arizona, New Mexico, Utah, Colorado, Alaska, Washington) process a disproportionate number of Artemis SCID TREC-low results relative to the general population. Population-specific screening workflows that include DCLRE1C founder mutation rapid testing alongside standard IL2RG, IL7R, and general SCID gene panel sequencing can accelerate genetic confirmation in Navajo/Apache newborns. Platforms supporting these population-specific workflows must maintain availability in the geographic regions where Navajo Nation and Apache community newborn screening sample processing occurs. Monitor with population-appropriate geographic redundancy.
Mixed chimerism surveillance platforms track the post-RIC engraftment landscape. Reduced-intensity conditioning achieves lower rates of full donor chimerism and higher rates of mixed chimerism than myeloablative conditioning — a tradeoff accepted in Artemis SCID to reduce conditioning toxicity. Mixed chimerism (donor T cells engrafting in a partly host myeloid environment) is often sufficient for immune reconstitution in Artemis SCID if the donor T-cell compartment achieves sufficient chimerism for functional immunity. Surveillance platforms tracking T-cell chimerism, myeloid chimerism, NK-cell chimerism, and B-cell chimerism at regular post-transplant timepoints must support interpretation of the mixed chimerism patterns that characterize RIC outcomes and alert on declining chimerism trajectories that may indicate graft failure or rejection. Monitor during clinical hours.
What to Monitor on an Artemis SCID Tech Platform
TREC Newborn Screening Alert and Diagnostic Coordination
Monitor TREC result ingestion records from newborn screening laboratory interfaces confirming real-time transmission of T-cell receptor excision circle quantification from dried blood spot cards, TREC-low alert dispatch records with particular attention to the T-B-NK+ immunophenotype pattern that distinguishes Artemis/RAG SCID from T-B+NK- (JAK3/SCID-X1) and T-B+NK+ (IL7R) SCID, absolute lymphocyte count reflex ordering records, lymphocyte subset flow cytometry ordering records documenting CD3/CD4/CD8/CD19/CD16/CD56 panel results, protective isolation advisory dispatch records, pediatric immunology referral coordination records, DCLRE1C founder mutation rapid testing ordering records for Navajo/Apache patients enabling accelerated genetic confirmation, comprehensive SCID gene panel sequencing ordering records, and DCLRE1C radiosensitivity documentation initiation records confirming that the Artemis SCID diagnosis triggers immediate radiosensitivity flag creation in the HSCT planning record. Alert immediately on TREC alert system failures.
Radiosensitivity Documentation and HSCT Conditioning Protocol Management
Monitor radiosensitivity flag creation records confirming that all confirmed Artemis SCID patients have a radiosensitivity designation captured in the HSCT planning record before conditioning protocol selection occurs, radiosensitivity flag transfer records confirming that the radiosensitivity designation transfers correctly when the patient record is accessed by referring HSCT centers, conditioning protocol selection confirmation records documenting that the HSCT team has selected reduced-intensity conditioning protocol on the basis of documented Artemis SCID diagnosis and radiosensitivity flag, busulfan pharmacokinetics monitoring records from the day-of-first-dose plasma concentration sampling with real-time area-under-curve calculation and dose-adjustment recommendation within the required timeframe before the next busulfan administration, fludarabine dosing records tracking the lymphodepleting component of the RIC protocol, serotherapy administration records (alemtuzumab or anti-thymocyte globulin dosing schedules and administration confirmation), conditioning toxicity monitoring records including liver function tests, buccal mucosa assessment, pulmonary function, and renal function at defined protocol timepoints during the conditioning admission, and RIC conditioning modification records for patients requiring protocol adjustments based on toxicity monitoring results. Alert immediately on radiosensitivity documentation system failures and on conditioning monitoring platforms during active conditioning admissions.
T-Cell and B-Cell Reconstitution Monitoring (Post-RIC HSCT)
Monitor absolute lymphocyte count records at each post-HSCT assessment timepoint from zero-T-cell and zero-B-cell baseline, CD3+ total T-cell count records — in Artemis SCID, any new CD3+ T cells post-HSCT are donor-derived since the patient had no T cells before transplant, CD4+ helper T-cell count records with attention to the CD4 above 200/μL threshold for prophylaxis weaning, CD8+ cytotoxic T-cell count records, CD16+/CD56+ NK cell count records — NK cells are present before transplant (T-B-NK+ immunophenotype) and must be tracked with chimerism studies to distinguish pre-existing host NK cells from donor NK cells, CD19+ B-cell count records tracking the transition from absent B cells pre-transplant to donor B-cell engraftment post-HSCT, immunoglobulin panel records tracking the transition from IVIG-supplemented serology to endogenous immunoglobulin production, T-cell receptor diversity records documenting polyclonal reconstitution from the RIC engraftment, mixed chimerism records at all lymphoid and myeloid compartments — particularly important in RIC Artemis SCID where split chimerism between lymphoid and myeloid compartments is common, and declining chimerism alert records flagging trajectories suggesting partial graft failure in the RIC setting where full myeloablation was not achieved. Monitor at 1-minute intervals during clinical hours.
Infection Prophylaxis — Enhanced Surveillance for Post-RIC Immunodeficiency
Monitor TMP-SMX prophylaxis scheduling records confirming active Pneumocystis prophylaxis from diagnosis through confirmed immune reconstitution, antifungal prophylaxis records — invasive Aspergillus and other mold infections are of particular concern in the post-RIC setting where prolonged immune reconstitution timelines may extend the at-risk interval, CMV surveillance records — CMV DNA PCR at regular post-HSCT timepoints, with close monitoring given that RIC conditioning provides less effective CMV-specific T-cell reconstitution in early post-transplant periods than myeloablative conditioning, adenoviral surveillance records — adenovirus PCR monitoring given lethal potential in T-cell-depleted patients, EBV surveillance records for post-transplant lymphoproliferative disorder (PTLD) risk in patients receiving alemtuzumab or ATG serotherapy as part of RIC conditioning, RSV prophylaxis records during RSV season, IVIG infusion scheduling records with IgG trough above 500–800 mg/dL threshold monitoring, prophylaxis weaning protocol records, and breakthrough infection documentation. Alert on sustained failures during clinical hours.
Navajo/Apache Population Health Screening
Monitor population-specific DCLRE1C founder mutation rapid testing workflow records for Navajo/Apache newborn screening positives enabling same-day genetic confirmation in affected communities, cascade family screening coordination records for extended family genetic testing following proband identification, Navajo Nation and Apache tribe health program coordination records documenting the interface between tribal health programs and state newborn screening programs for TREC-positive result transmission, culturally adapted family counseling scheduling records for genetic diagnosis communication in Navajo/Apache families, transportation and housing support coordination records for families in remote Navajo Nation or Apache reservation areas requiring travel to pediatric HSCT programs for treatment, and HSCT outcome tracking records for Navajo/Apache patients contributing to the population-level DCLRE1C founder mutation outcome database. Monitor during clinical and business hours.
Growth and Developmental Assessment Scheduling
Monitor anthropometric measurement records at clinical visits tracking weight, height, and head circumference trajectory against age-appropriate growth curves for post-HSCT Artemis SCID patients, developmental milestone assessment scheduling records at defined intervals from HSCT through childhood, early intervention referral records for patients with developmental delays, and school-age neuropsychological evaluation records for patients with pre-diagnosis neurological exposures or post-HSCT developmental concerns. Monitor during business hours.
Live Vaccine Contraindication Alert System
Monitor live vaccine contraindication flags on all Artemis SCID patient records confirming BCG, MMR, varicella, rotavirus, and other live vaccine contraindications are flagged until immune reconstitution is formally confirmed, vaccine order interception records for any live vaccine order on an Artemis SCID patient, immune reconstitution confirmation records documenting the criteria for lifting the contraindication, and notification records when immune reconstitution criteria are confirmed and the contraindication is cleared. Alert immediately on vaccine contraindication alert system failures.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. Artemis SCID management during the neonatal period and HSCT conditioning admission requires urgent concurrent access from TREC screening coordinators, pediatric immunology, HSCT conditioning pharmacokinetics, infectious disease, Navajo/Apache tribal health programs, and genetics teams — authentication failures during the conditioning period are immediately clinically dangerous.
SSL Certificates
Monitor SSL certificate expiry across TREC alert systems, radiosensitivity documentation portals, HSCT conditioning monitoring platforms, chimerism surveillance systems, prophylaxis scheduling portals, Navajo/Apache population health program interfaces, and developmental assessment systems. Certificate errors in TREC alert systems or radiosensitivity documentation portals create immediate patient safety risk.
HIPAA and Artemis SCID Genetic Data Privacy Considerations
Artemis SCID technology platforms handle PHI categories including DCLRE1C biallelic pathogenic variant records — with particular sensitivity for Navajo Nation and Apache population records where the founder mutation has significant community prevalence and cascade testing implications for extended family networks, radiosensitivity designation records creating a documented DNA repair defect with long-term implications for avoidance of ionizing radiation and radiomimetic exposures beyond the HSCT context, neonatal SCID records with life-threatening prognosis, pediatric HSCT records including RIC protocol documentation with long-term health implications, tribal health program records requiring coordination with tribal health authorities under unique sovereignty-respecting frameworks beyond standard HIPAA provisions, and population genetic data from Navajo/Apache communities requiring heightened sensitivity to the historical context of medical research and genetic data collection in Indigenous communities. HIPAA Security Rule protections apply across all platform components with particular attention to Indigenous community records and DCLRE1C variant documentation.
Alerting Strategy for Artemis SCID Tech Platforms
Immediate 24/7 alerting: TREC newborn screening alert dispatch; authentication; live vaccine contraindication alert systems; radiosensitivity documentation systems.
Immediate clinical-hours alerting: T-cell and B-cell reconstitution monitoring; mixed chimerism surveillance; HSCT conditioning monitoring during active conditioning admissions; busulfan pharmacokinetics platform during conditioning.
Immediate alerting during active care periods: Infection prophylaxis platforms during pre-HSCT and post-RIC intervals; CMV and EBV surveillance during alemtuzumab/ATG serotherapy recovery; IVIG trough monitoring when approaching threshold.
Sustained-failure alerting (10–15 minutes): Navajo/Apache population health program interfaces; growth and developmental assessment scheduling; antifungal prophylaxis coordination; SCIG infusion management.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms Artemis SCID platform availability from the geographies where pediatric HSCT programs with Artemis SCID and RIC protocol expertise, TREC newborn screening programs in states with Navajo Nation and Apache populations, tribal health program interfaces, and pediatric immunology centers managing DNA repair SCID concentrate.
Status Page for Artemis SCID Care Team Communication
A real-time status page gives newborn screening coordinators transmitting TREC-low results, pediatric immunologists reviewing T-cell reconstitution curves, HSCT coordinators monitoring RIC protocol pharmacokinetics, infectious disease consultants tracking CMV and EBV surveillance, Navajo/Apache tribal health program coordinators, and families managing their infant's care immediate platform visibility without requiring IT support contact.
Include the status page URL in newborn screening program emergency procedures, HSCT conditioning protocol documentation, Navajo/Apache tribal health program coordination materials, and infection prophylaxis coordination after-hours contacts.
Vigilmon Setup for Artemis SCID Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | TREC newborn screening alert dispatch | 1 min | Slack + PagerDuty (24/7) | | Live vaccine contraindication alert system | 1 min | Slack + PagerDuty (24/7) | | Radiosensitivity documentation system | 1 min | Slack + PagerDuty (24/7) | | T-cell / B-cell reconstitution monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Mixed chimerism surveillance | 1 min | Slack + PagerDuty (clinical hours) | | Busulfan PK monitoring (conditioning admission) | 1 min | Slack + PagerDuty (conditioning periods) | | CMV surveillance PCR monitoring | 1 min | Slack + PagerDuty (post-transplant periods) | | EBV / PTLD surveillance | 1 min | Slack (post-serotherapy periods) | | Antifungal prophylaxis coordination | 2 min | Slack (clinical hours) | | IVIG / SCIG scheduling and trough monitoring | 2 min | Slack (clinical hours) | | Navajo/Apache population health program interface | 2 min | Slack (business hours) | | Growth and developmental assessment scheduling | 2 min | Slack (business hours) | | Patient portal / family communication | 2 min | Slack (extended hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 PagerDuty alerting
- Configure TREC newborn screening alert dispatch at 1-minute intervals with 24/7 alerting
- Add live vaccine contraindication alert systems at 1-minute intervals with 24/7 alerting
- Configure radiosensitivity documentation systems at 1-minute intervals with 24/7 alerting
- Add T-cell and B-cell reconstitution monitoring with immediate clinical-hours alerting
- Configure mixed chimerism surveillance with immediate clinical-hours alerting
- Add busulfan pharmacokinetics monitoring with immediate alerting during active conditioning admissions
- Configure CMV and EBV surveillance with immediate alerting during post-transplant periods
- Add infection prophylaxis coordination (TMP-SMX, antifungal) with sustained-failure alerting during clinical hours
- Configure IVIG/SCIG scheduling and trough monitoring with sustained-failure alerting
- Add Navajo/Apache population health program interface monitoring with sustained-failure alerting
- Enable SSL certificate monitoring across all TREC systems, radiosensitivity documentation portals, and HSCT platforms
- Add the status page URL to newborn screening emergency procedures, HSCT conditioning protocols, and tribal health program coordination materials
Conclusion
Artemis SCID technology platforms carry monitoring obligations shaped by a distinguishing feature that has no parallel in any other SCID form: the DNA repair defect that makes Artemis SCID lethal without HSCT also makes standard HSCT conditioning lethal without the protocol modification that only a correctly documented and correctly transmitted radiosensitivity designation can mandate — which means that a radiosensitivity documentation platform failure in Artemis SCID is not a records management problem but a patient safety failure chain that begins with the absence of a flag in a clinical record and can end with the application of a myeloablative busulfan and cyclophosphamide conditioning regimen to a child whose DCLRE1C-deficient cells cannot repair the DNA double-strand breaks those drugs are designed to cause, producing hepatic veno-occlusive disease, mucositis, pulmonary toxicity, and treatment-related mortality in a patient who, had the radiosensitivity flag been correctly transmitted and the reduced-intensity conditioning protocol correctly selected, would have survived transplant and achieved immune reconstitution with a favorable outcome; a TREC alert dispatch failure for a Navajo newborn on a reservation in northeastern Arizona — where a DCLRE1C founder mutation deletion found in approximately 1 in 2,000 Navajo live births makes Artemis SCID twenty-five times more common than in the general population — is not a statistical anomaly but a high-probability clinical event in a population where the newborn screening program's TREC alert infrastructure is the difference between pre-symptomatic HSCT (excellent outcome) and the presentation with Pneumocystis pneumonia at 3 months of age that characterized Artemis SCID outcomes before newborn screening; a busulfan pharmacokinetics monitoring platform unavailable during the post-first-dose concentration sampling on day minus-6 of reduced-intensity conditioning for an Artemis SCID patient means the transplant pharmacist cannot calculate the area-under-curve that determines whether the busulfan dose requires adjustment — and without that calculation, the HSCT team must choose between delaying the conditioning day-minus-5 dose (disrupting the protocol and risking inadequate myelosuppression for engraftment) or administering the dose at the protocol-specified level without PK-based adjustment (risking either subtherapeutic myelosuppression or, worse, busulfan overexposure with excessive DNA damage in a patient whose repair capacity is already compromised by DCLRE1C deficiency); a mixed chimerism surveillance platform unavailable at the month-6 post-RIC HSCT timepoint for an Artemis SCID patient who achieved initial mixed chimerism (70% donor T cells, 40% donor myeloid) means the immunology team cannot review the trajectory that shows declining T-cell chimerism from 70% at month 3 to 55% at month 6 — a trend that, if detected, would prompt urgent evaluation for graft rejection and consideration of donor lymphocyte infusion or second transplant, but which, if not detected due to platform unavailability, allows the chimerism loss to progress to immune reconstitution failure with recurrent infections; and an EBV surveillance platform unavailable at the 3-month post-alemtuzumab serotherapy assessment for an Artemis SCID patient receiving ciclosporin for GVHD prophylaxis means the infectious disease team cannot detect the rising EBV viral load that, in a profoundly T-cell-depleted patient with serotherapy-mediated B-cell depletion recovery underway, signals post-transplant lymphoproliferative disorder — a potentially fatal complication treatable with rituximab if detected early and catastrophic if detected after end-organ involvement. These are not IT incidents. They are clinical failures in the care of children with a DNA repair SCID whose management complexity — radiosensitivity documentation, reduced-intensity conditioning, mixed chimerism surveillance, population-specific care for Navajo and Apache communities — demands platform reliability as robust as the clinical protocols it supports.
Uptime monitoring gives Artemis SCID tech teams the detection capability to identify platform failures within seconds, activate clinical downtime procedures protecting radiosensitivity documentation, TREC alert pathways, conditioning pharmacokinetics monitoring, and chimerism surveillance during outages, and demonstrate to pediatric HSCT programs, Navajo Nation and Apache tribal health programs, newborn screening agencies, and families that platform operational reliability matches the life-critical complexity of DNA repair SCID management.
Start monitoring your Artemis SCID care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #ArtemisSCID #DCLRE1C #Artemisdeficiency #DNArepairSCID #radiosensitiveSCID #NavajaSCID #SCID #primaryImmunodeficiency #TBMINUSNKPLUS #HSCT #reducedIntensityConditioning #VDJrecombination #newbornScreening #TREC #mixedChimerism #busulfanPK #pediatricImmunology #IndigenousHealth #HIPAA #healthtech #digitalhealth #uptime #sre